Viamet Pharmaceuticals was an American pharmaceutical company based in the Research Triangle of North Carolina. The company discovered and developed “small-molecule inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach” called “Metallophile™ Technology.”[1]
History
Viamet was founded in 2005 by Thomas O'Halloran and Holden Thorp.[2][3]
On June 3, 2015, Viamet announced it had been awarded a $1.95 million grant from the United States Department of Defense to develop “a novel topical antifungal agent to prevent and treat mold infections as a result of battlefield wounds.”[4]
On January 3, 2018, Viamet announced it had been acquired by NovaQuest Capital Management.[5] Its operations continued under a newly-founded NovaQuest portfolio company called Mycovia Pharmaceuticals.[6]
Organization
Investors in Viamet included:[7][8]
- Astellas Venture Management
- Hatteras Venture Partners
- Headlands Ventures
- Intersouth Partners
- Lilly Ventures
- Lurie Investment Fund
- Novartis Venture Fund
- United States Department of Defense
External links
Our Company. Viamet Pharmaceuticals. Retrieved January 3, 2009, from http://archive.today/2009.01.03-114852/http://www.viamet.com/viamet.asp?id=269&category=2 ↩︎
Viamet Pharmaceuticals - Crunchbase Company Profile & Funding. Crunchbase. Retrieved May 18, 2023, from https://www.crunchbase.com/organization/viamet-pharmaceuticals ↩︎
Founders. Viamet Pharmaceuticals. Retrieved January 5, 2009, from http://archive.today/2009.01.05-073153/http://www.viamet.com/viamet.asp?id=282&category=2 ↩︎
Katz, R. (2015, June 3). Viamet Announces Awarding Of Department Of Defense Grant. BioSpace. http://archive.today/2023.05.18-215031/https://www.biospace.com/article/releases/viamet-announces-awarding-of-b-department-of-defense-b-grant-/?s=80 ↩︎
Tuck, S., & MacDougall Biomedical Communications. (2018, January 3). NovaQuest Capital Management to Acquire Viamet Pharmaceuticals and the VT-1161 Antifungal Program. Bloomberg. http://archive.today/2023.05.18-213244/https://www.bloomberg.com/press-releases/2018-01-03/novaquest-capital-management-to-acquire-viamet-pharmaceuticals-and-the-vt-1161-antifungal-program ↩︎
Teater, B. (2022, April 29). Durham startup Mycovia wins FDA approval for new antifungal drug. WRAL TechWire. https://web.archive.org/web/20230518213439/https://wraltechwire.com/2022/04/29/durham-startup-mycovia-wins-fda-approval-for-new-antifungal-drug/ ↩︎
Investors. Viamet Pharmaceuticals. Retrieved January 5, 2009, from http://archive.today/2009.01.05-073204/http://www.viamet.com/viamet.asp?id=284&category=2 ↩︎
Viamet Pharmaceuticals - Funding, Financials, Valuation & Investors. Crunchbase. Retrieved May 18, 2023, from https://www.crunchbase.com/organization/viamet-pharmaceuticals/company_financials ↩︎
